Dr. Sehouli on Considering Secondary Cytoreductive Surgery in Ovarian Cancer

Jalid Sehouli, MD
Published Online: Friday, Nov 10, 2017



Jalid Sehouli, MD, professor, director of the Clinic Campus Virchow and Campus Benjamin Franklin Charité Center Gynecology, Charité – Universitatsmedizin Berlin, advises physicians on considering secondary cytoreductive surgery in ovarian cancer.

Sehouli’s advice for physicians that are considering secondary cytoreductive surgery for their patients is to take in account previous treatment, tumor pattern, and symptoms. From there, they must define a treatment goal and consider the infrastructure of their institution.
 


Jalid Sehouli, MD, professor, director of the Clinic Campus Virchow and Campus Benjamin Franklin Charité Center Gynecology, Charité – Universitatsmedizin Berlin, advises physicians on considering secondary cytoreductive surgery in ovarian cancer.

Sehouli’s advice for physicians that are considering secondary cytoreductive surgery for their patients is to take in account previous treatment, tumor pattern, and symptoms. From there, they must define a treatment goal and consider the infrastructure of their institution.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: The Expanding Role of PARP Inhibitors in the Treatment of Ovarian Cancers – Current Strategies and Future DirectionJan 30, 20181.5
Clinical Vignette Series: 34th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®Feb 28, 20182.0
Publication Bottom Border
Border Publication
x